Increased Risk Of Major And Minor Bleeding During Antiplatelet Therapy

Increased Risk Of Major And Minor Bleeding During Antiplatelet Therapy.
Risk of bleeding for patients on antiplatelet group therapy with either warfarin or a bloc of Plavix (clopidogrel) and aspirin is substantial, a unfamiliar bookwork finds. Both therapies are prescribed for millions of Americans to delay life-threatening blood clots, especially after a affection attack or stroke homepage. But the Plavix-aspirin clique was thought to cause less bleeding than it actually does, the researchers say.

And "As with all drugs, these drugs come with risks; the most straight-faced is bleeding," said diva author Dr Nadine Shehab, from the US Centers for Disease Control and Prevention (CDC). While the danger of bleeding from warfarin is well-known, the risks associated with dual remedial programme were not well understood. "We found that the peril for hemorrhage was threefold higher for warfarin than for dual antiplatelet therapy. We expected that because warfarin is prescribed much more commonly than dual antiplatelet therapy".

However, when the researchers took the few of prescriptions into account, the delay between warfarin and dual antiplatelet cure shrank. "And this was worrisome". For both regimens, the company of hospital admissions because of bleeding was similar. And bleeding-related visits to exigency department visits were only 50 percent trim for those on dual antiplatelet therapy compared with warfarin. "This isn't as big a dissimilitude as we had thought".

For the study, published Monday in the Archives of Internal Medicine, Shehab's crew used national databases to label emergency department visits for bleeding caused by either dual antiplatelet psychotherapy or warfarin between 2006 and 2008. The investigators found 384 annual difficulty department visits for bleeding all patients taking dual antiplatelet therapy and 2,926 annual visits for those taking warfarin.